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Aims Aortic valve stenosis is commonly considered a degenerative disorder with no recommended preventive interven-
tion, with only valve replacement surgery or catheter intervention as treatment options. We sought to assess the




Causality of association was assessed using two-sample Mendelian randomization framework through different stat-
istical methods. We retrieved summary estimations of 157 genetic variants that have been shown to be associated
with plasma lipid levels in the Global Lipids Genetics Consortium that included 188 577 participants, mostly
European ancestry, and genetic association with aortic stenosis as the main outcome from a total of 432 173 partic-
ipants in the UK Biobank. Secondary negative control outcomes included aortic regurgitation and mitral regurgita-
tion. The odds ratio for developing aortic stenosis per unit increase in lipid parameter was 1.52 [95% confidence
interval (CI) 1.22–1.90; per 0.98 mmol/L] for low density lipoprotein (LDL)-cholesterol, 1.03 (95% CI 0.80–1.31;
per 0.41 mmol/L) for high density lipoprotein (HDL)-cholesterol, and 1.38 (95% CI 0.92–2.07; per 1 mmol/L) for
triglycerides. There was no evidence of a causal association between any of the lipid parameters and aortic or mi-
tral regurgitation.
...................................................................................................................................................................................................
Conclusion Lifelong exposure to high LDL-cholesterol increases the risk of symptomatic aortic stenosis, suggesting that LDL-
lowering treatment may be effective in its prevention.
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Introduction
A marked shift in the epidemiology of valvular heart disease has been
observed in the past century.1 Degenerative valve disease, typically
manifesting as aortic stenosis or mitral regurgitation, has replaced
rheumatic valve disease as the leading cause of valvular heart disease,
a trend fuelled by population ageing and increased prevalence of
cardiovascular risk factors.2,3 However, medical treatment for valvu-
lar heart disease remains limited and many patients would eventually
need valve surgery or catheter-based valve repair or replacement.4
Such procedures are associated with significant complications and
are costly, with recent estimates suggesting that procedural costs
amount to £10 000 and £16 000 for surgical and catheter-based inter-
ventions in the UK.5
* Corresponding author. Tel: þ44 1865 617200, Fax: þ44 1865 617202, Email: kazem.rahimi@georgeinstitute.ox.ac.uk
VC The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
European Heart Journal (2020) 0, 1–10 CLINICAL RESEARCH































































































Poor understanding of the underlying mechanisms and risk factors
for initiation and progression of valvular heart disease has hindered
the development of effective medical treatment for primary and sec-
ondary prevention. Considering the shared aetiological pathways be-
tween different types of cardiovascular disease,6–8 several risk factors
have been investigated, but findings for dyslipidaemia have been in-
consistent. Whilst observational studies have suggested a potential
association between dyslipidaemia and risk of aortic stenosis,9
randomized controlled trials (RCTs) have not demonstrated any ef-
fect of statin therapy on progression of aortic stenosis.10–12
However, RCTs have been based on mostly small sample sizes, rela-
tively short follow-up, and inclusion of patients with established
disease.
With this limited evidence from observational and interventional
studies, Mendelian randomization (MR) offers an opportunity to effi-
ciently and reliably investigate the potential causal association be-
tween dyslipidaemia and valvular heart disease. Mendelian
randomization uses instrumental variable analysis to mimic the ran-
domization process that underpins causal inference in RCTs. It is an
approach that takes advantage of the naturally occurring random allo-
cation of alleles inherited by offspring from their parents during the
formation of the zygote (Supplementary material online, Figure S1).
This process is similar to the random allocation of treatment in RCTs
and could therefore overcome the problems of reverse causation
and confounding inherent in observational studies.13 We aimed to
use MR techniques to test the hypothesis that elevated plasma lipids
are causally related to the risk of incident aortic stenosis.
Methods
Data for exposure
Our main exposure was genetically determined plasma lipids as instru-
mental variable. This was estimated from genetic variants that were asso-
ciated with levels of low density lipoprotein (LDL)-cholesterol, high
density lipoprotein (HDL)-cholesterol, triglycerides, and total cholesterol
at genome-wide significance level. We retrieved summary estimations of
157 genetic variants that have been shown: (i) to be associated with
plasma lipid levels in the Global Lipids Genetics Consortium (GLGC)
genome-wide association study (P < 5 10-8) that included 188 577 par-
ticipants, mostly European ancestry and (ii) were independently associ-
ated with plasma lipid levels (linkage disequilibrium threshold of r2 < 0.01
and located 1 Mb apart from each other) (Supplementary material online,
Datasets S1–S4).14 A detailed description of the statistical methods and
quality control is provided in a previous publication by the GLGC.14
Briefly, as in most studies included in the GLGC, plasma lipid concentra-
tions had been measured after at least 8 h fasting, and the estimations
were adjusted for age, age squared, sex, and population stratification.
Participants with known lipid-lowering medication use have been
excluded from study.14 Selected genetic variants together explained 10–
14% of the total trait variance.14 Additive genetic models using linear re-
gression on the inverse normal transformed traits were fitted for individ-
ual variant association estimates, and a weighted meta-analysis using
Stouffer method was conducted for combined estimates.14 The effect
sizes were calculated with respect to the minor allele per 1 SD increase
in plasma lipid levels (1 SD is equal to 0.98 mmol/L for LDL-cholesterol,
0.41 mmol/L for HDL-cholesterol, 1 mmol/L for triglycerides, and
1.10 mmol/L for total cholesterol).14
Data for outcome
We used the UK Biobank data, a large prospective cohort study including
502 602 participants aged 40–69 years and recruited between 2006 and
2010 from 22 assessment centres across the UK. Details of the study de-
sign have been published elsewhere.15,16 UK Biobank genotype data were
imputed with IMPUTE4 using the Haplotype Reference Consortium and
the UK10Kþ 1000 Genomes panel17 to identify 96 million variants for
487 381 participants. We excluded 55 208 individuals who were outliers
based on heterozygosity, had a variant call rate <98%, or were not
recorded as ‘white British’. The remaining participants (n = 432 173) were
included in the estimation of genetic variants-outcome association in this
study. The protocol of the present study was approved by UK Biobank
(#22207).
Aortic stenosis was the primary outcome, with aortic regurgitation
and mitral regurgitation as the negative control secondary outcomes
(Supplementary material online, Text S1). We calculated corresponding
summary statistics for the outcomes using logistic regression model
adjusted for age, sex, assessment centre, genetic batch, the first 10 genetic
principal component (for addressing population stratification), and up to
third-degree relatedness based on kinship coefficients (>0.044).
Statistical analysis
Two-sample Mendelian randomization to assess total
causal effect
We harmonized summary data based on a previously described
method.18 Then, we used four different methods of two-sample MR [in-
verse-variance weighted (random-effects model), weighted median, MR-
Egger, and MR-PRESSO] in order to address between variants heterogen-
eity and pleiotropy effect. The inverse-variance weighted method
assumes that either all the instruments are valid or any horizontal plei-
otropy is balanced.19 We provided an estimation using the weighted me-
dian method, which is consistent if at least 50% of the weight comes from
valid instrumental variables.20 The MR-Egger regression method was
used as the main estimation to account for potential pleiotropy.21 In add-
ition, the MR pleiotropy residual sum and outlier (MR-PRESSO) method
was used to test, and correct, if needed, for possible horizontal pleiotrop-
ic outliers in the analysis.22
We considered the association as causal when at least three methods
provided consistent results. This approach reduces the risk of false-posi-
tive interpretation, and demonstration of consistent findings across the
various models is likely to strengthen the case for a causal association.
We used a predefined approach to select the best statistical estimation
from these four methods (see Supplementary material online, Figure S2
for details). A leave-one-out sensitivity analysis was conducted by remov-
ing a single variant from the analysis in turn. The fluctuation of the esti-
mates in response to excluding each variant reflects the possibility of
outlier variant in the causal estimation. We examined the heterogeneity
of the estimates using a scatter plot and applying the Cochran’s Q-test.23
We also assessed the probable directional pleiotropy using a funnel plot
similar to that being used to assess for publication bias in meta-analysis.23
The minimum detectable odds ratio (OR) was calculated using the
method reported by Brion et al.24, and implemented in a web-based appli-
cation (Supplementary material online, Table S1). In addition to using
negative control outcomes, we tested the validity of the instrumental
variable by examining the causal association between plasma lipids and
coronary heart disease as a positive outcome for LDL-cholesterol, total
cholesterol, and triglycerides and a negative outcome for HDL-choles-
terol.25 For this control analysis, we used two-sample MR using an analyt-
ical platform.26 We used the same genetic variants for plasma lipids, but
the variants-outcome association was extracted from a large genome-
wide association study meta-analysis including 22 233 individuals with































































































coronary heart disease and 64 762 controls of European population.27
To address the possible mediating effect of myocardial infarction and
heart failure on the association between lipid profile and aortic stenosis,
we performed sensitivity analysis that excluded individuals with myocar-
dial infarction and/or heart failure. In addition, to assess the robustness of
the findings, we restricted cases to those with aortic stenosis and aortic
valve replacement surgery. All the statistical analyses were performed
using R software (‘MendelianRandomization’28 and ‘TwoSampleMR’26
packages).
Multivariable Mendelian randomization to assess the
direct causal effect
We used multivariable MR through inverse-variance weighted method to
estimate the direct causal effect of lipid profile on the outcomes. We
excluded total cholesterol from this analysis because of observable over-
lap between total and LDL-cholesterol. In cases where the exposures of
interest are correlated, such as total and LDL-cholesterol, the multivari-
able MR is useful to estimate direct causal effect of each lipid profile com-
ponent, independently of any other lipid profile variables.29,30 Given that
a causal link between elevated lipoprotein-a [LP(a)] and aortic stenosis
has been reported,31 we repeated the multivariable MR additionally
adjusted for LP(a) to further check the possible effect of LP(a) on the
associations. The biochemistry and genetic data for LP(a) have been
obtained from the UK Biobank resource.
Results
Main findings
The characteristics of the populations included in the GLGC and UK
Biobank are shown in Table 1. In the UK Biobank, we identified 1961
participants with aortic stenosis, 736 with aortic regurgitation, and
2213 with mitral regurgitation. Table 2 shows the results of MR for
aortic stenosis. There was clear evidence of a causal effect of LDL-
cholesterol, total cholesterol, and triglycerides on aortic stenosis
(P < 0.05 in the three MR methods) (Table 2 and Supplementary ma-
terial online, Figure S3). Considering the best causal estimation, the
OR was 1.64 [95% confidence interval (CI) 1.28–2.11] per
0.98 mmol/L increase in LDL-cholesterol, 1.82 (95% CI 1.32–2.53)
per 1.10 mmol/L increase in total cholesterol, and 1.55 (95% CI 1.20–
2.00) per 1 mmol/L increase in triglycerides. The findings were also
concordant on the lack of association between HDL-cholesterol and
aortic stenosis. There was no evidence in favour of an association be-
tween plasma lipid parameters and aortic or mitral regurgitation,
other than for a weak association between triglycerides and mitral re-
gurgitation (Tables 3 and 4). However, the latter finding was only sup-
ported by one of the methods whilst all other methods consistently
showed null associations between all lipid parameters and aortic and
mitral regurgitation (Supplementary material online, Figure S3).
Figure 1 compares the risk estimates from the MR analyses separately
for each outcome. There was no evidence of directional pleiotropy
except for total cholesterol (beta = -0.009; P = 0.04 in MR-Egger
intercept) (Table 2). The funnel plots show an absence of directional
pleiotropy, with a symmetrical distribution of variants effects
(Supplementary material online, Figures S4–S11). However, there was
significant heterogeneity for all lipid parameters. The control analysis
with coronary heart disease as the outcome showed positive and sig-
nificant association with each of lipid parameters other than for
HDL-cholesterol, confirming that the selected genetic variants were
valid instruments (Supplementary material online, Figure S12).
Sensitivity analysis
To assess the potential mediating effect of a presentation with myo-
cardial infarction or heart failure on detection of valve disease, we
repeated the analysis excluding all the participants with documented
myocardial infarction and/or heart failure. The findings were broadly
similar to the overall analysis, other than for a reduction in pleiotropy
in total cholesterol analysis after excluded participants with myocar-
dial infarction (MR-Egger intercept = -0.005; P = 0.59) (Supplemen-
tary material online, Tables S2–S4 and Figure S13). There were also no
substantial differences in the results after excluding participants with
heart failure (Supplementary material online, Figure S14). Sensitivity
analysis by restricting the outcome only to include those with valve
replacement therapy was consistent with the main results
(Supplementary material online, Figure S15). In the leave-one-out ana-
lysis, we found that no single genetic variant was strongly driving the
overall effect of plasma lipids on aortic stenosis (Supplementary ma-
terial online, Figures S16–S19).
In the multivariable MR that adjusted for the effect of each lipid
profile component, the strong positive association between LDL-
cholesterol and aortic stenosis persisted, whereas the association
with triglycerides was attenuated. The multivariable-adjusted ORs
were 1.52 (95% CI 1.22–1.90; per 0.98 mmol/L increase) for LDL-
cholesterol, 1.38 (95% CI 0.92–2.07; per 1 mmol/L increase) for tri-
glycerides, and 1.03 (95% CI 0.80–1.31; per 0.41 mmol/L increase) for
HDL-cholesterol (Figure 2). Additional adjustment for LP(a) did not
change the results (Supplementary material online, Figure S20).
Discussion
This study showed that each standard deviation increase in LDL-
cholesterol, total cholesterol, and triglycerides increases the risk of
incident aortic stenosis by 64%, 82%, and 55%, respectively. In con-
trast, there was no evidence of a causal association between plasma
lipids and aortic regurgitation or mitral regurgitation. After adjust-
ment for each lipid profile component through multivariable MR, the
result corroborated the association between LDL-cholesterol and
risk of aortic stenosis. However, the findings for triglycerides were in-
conclusive and should be interpreted with caution. This is in part be-
cause of the small numbers of independent genetic variants available
for triglycerides which could have led to a low statistical power and
wide CIs. Nevertheless, the robustness and consistency of our results
using different methods, together with the strength of the association,
indicate an unconfounded relationship between elevated LDL-
cholesterol with the risk of incident aortic stenosis, and suggest that
this association is likely to be causal.
This MR study is in keeping with a previous population-based co-
hort study suggesting that dyslipidaemia was associated with an
increased risk of incident aortic stenosis.9 However, the observation-
al nature of this earlier report precluded drawing conclusions about
causality and the binary categorization of dyslipidaemia limited the
study from demonstrating any dose–response relationship. More re-
cently, a one-sample MR study, which included 473 cases of aortic
stenosis, demonstrated a causal association between LDL-











..cholesterol and aortic stenosis, with no evidence of a significant asso-
ciation with triglycerides.32 However, the latter may be due to lack of
power to detect a small effect size, which is indeed a known limitation
when conducting one-sample MR.33 Our two-sample analysis, based
on data from two non-overlapping datasets, has a higher power than




Table 1 Characteristics of Global Lipids Genetics Consortium and UK Biobank datasets
Exposures Consortium No. SNPs Sample size Population
HDL-cholesterol GLGC 71 92 860 90% European
LDL-cholesterol 57 83 198
Total cholesterol 73 92 260
Triglycerides 40 91 598
Main outcomes Dataset No. cases/sample size Population
Aortic stenosis UK Biobank 1961/432 173 100% European
Aortic regurgitation 736/432 173
Mitral regurgitation 2213/432 173
Outcomes for sensitivity analysis
Myocardial infarction 15 391/432 173
Heart failure 5161/432 173
Aortic valve replacement 1233/432 173
Demographic variables
Age (years), mean (SD) 56.8 (8.0)
Male gender, n (%) 198 623 (45.9)





Table 2 Two-sample Mendelian randomization estimations showing the effect of plasma lipids on aortic stenosis
Methods Exposure Odds ratioa 95% CI P-value Ph Q-statistics
Inverse-variance weighted HDL-cholesterol 0.86 0.69 1.06 0.17 <0.001 117.1
MR-Egger 0.98 0.70 1.37 0.91
Weighted median 0.99 0.76 1.29 0.93
MR-PRESSOb NA NA NA NA
MR-Egger interceptc -0.009 -0.026 0.008 0.31
Inverse-variance weighted LDL-cholesterol 1.58 1.30 1.91 <0.001 0.01 81.6
MR-Egger 1.63 1.19 2.24 <0.001
Weighted median 1.64 1.28 2.11 <0.001
MR-PRESSO 1.59 1.34 1.90 <0.001
MR-Egger interceptc -0.002 -0.022 0.017 0.80
Inverse-variance weighted Total cholesterol 1.60 1.33 1.92 <0.001 0.04 93.7
MR-Egger 1.82 1.32 2.53 <0.001
Weighted median 1.73 1.33 2.25 <0.001
MR-PRESSOb NA NA NA NA
MR-Egger interceptc -0.009 -0.026 0.009 0.04
Inverse-variance weighted Triglycerides 1.52 1.12 2.03 0.006 <0.001 77.5
MR-Egger 1.49 0.95 2.33 0.08
Weighted median 1.39 1.00 1.92 0.05
MR-PRESSO 1.55 1.20 2.00 0.002
MR-Egger interceptc 0.001 -0.024 0.026 0.91
The best causal estimation highlighted in bold .
CI, confidence interval; HDL, high density lipoprotein; LDL, low density lipoprotein; NA, not applicable; Ph, P-value for heterogeneity.
aOdds ratio per 1 SD increase.
bNo significant outliers.
cRegression coefficient (95% CI).













































..addition, we were able to overcome the issue of weak instrument
bias, which may underpin the underestimation of a causal association
between triglycerides and aortic stenosis in the aforementioned
study.35 However, the apparent causal association between raised tri-
glycerides and aortic stenosis was attenuated by adjustment for the
effect of other lipid markers. This adjustment substantially reduced
the number of variants available as these variants needed to be asso-
ciated with raised triglycerides but not with cholesterol markers.
Therefore, the independent association between raised triglycerides
and aortic stenosis remains uncertain. A similar issue is seen when
assessing the direct causal effect of triglycerides on coronary heart
disease, where the small number of genetic variants precluded pre-
cise causal estimation of the association using MR technique.30
Our findings are supported by pathophysiological studies which
have shown the involvement of an atherosclerotic process of the
valve cusps in aortic stenosis, similar to what happens in the arterial
tree.36–38 It is thus biologically plausible that well-established causal
factors in the development of atherosclerosis, particularly in the cor-
onary arteries, maybe also be involved in the pathological process of
aortic stenosis.39,40 Cholesterol, and more specifically, LDL-
cholesterol, is a clearly established risk factor of atherosclerotic dis-
eases, whilst the role of triglycerides as an independent risk factor
remains controversial.41–43 In addition, although experimental studies
have suggested that components of HDL particles may have positive
effects on aortic stenosis, we did not find an association between
genetically determined HDL-cholesterol levels and risk of aortic sten-
osis.44 This is in keeping with the lack of effect of HDL-raising treat-
ments for primary and secondary prevention of coronary artery
disease consistently reported by both RCTs45,46 and MR studies.47
Therefore, further evidence is warranted to understand the role of
HDL-cholesterol in aortic stenosis pathogenesis and whether
increasing HDL-cholesterol level could have a beneficial impact in
delaying the disease progression.
To the best of our knowledge, no RCT has yet assessed the effect
of lipid modification for primary prevention of aortic stenosis.
However, three randomized trials have investigated the effects of sta-
tins in patients with mild to moderate aortic stenosis. Although these
trials failed to show a clear benefit for LDL-lowering therapy in delay-
ing the progression of aortic stenosis to eventually require aortic
valve replacement,10–12,48 they were mostly limited by a short
follow-up duration and insufficient statistical power.10,11,48 Indeed,
detecting a relatively small treatment effect on a slowly progressive
disease will likely require a substantially large sample size. In addition,
our MR analysis reflects the impact of lifelong exposure to higher lev-
els of cholesterol and triglycerides, capturing long-term risks that
may not be modifiable by short-term lipid-lowering treatment.49
Indeed, it is possible that cholesterol-induced atherosclerosis plays a
more important role in initiation than in progression of aortic sten-
osis, which, for practical reasons, has been the main outcome of ear-





Table 3 Two-sample Mendelian randomization estimations showing the effect of plasma lipids on aortic regurgitation
Methods Exposure Odds ratioa 95% CI P-value Ph Q-statistics
Inverse-variance weighted HDL-cholesterol 0.87 0.66 1.15 0.35 0.40 72.1
MR-Egger 0.82 0.53 1.25 0.35
Weighted median 0.73 0.47 1.13 0.15
MR-PRESSOb NA NA NA NA
MR-Egger interceptc 0.005 -0.017 0.027 0.65
Inverse-variance weighted LDL-cholesterol 0.97 0.73 1.30 0.88 0.09 70.2
MR-Egger 0.94 0.59 1.51 0.80
Weighted median 1.10 0.73 1.66 0.63
MR-PRESSOb NA NA NA NA
MR-Egger interceptc 0.003 -0.027 0.33 0.83
Inverse-variance weighted Total cholesterol 0.87 0.67 1.13 0.32 0.51 70.9
MR-Egger 1.06 0.67 1.69 0.80
Weighted median 1.11 0.74 1.69 0.61
MR-PRESSOb NA NA NA NA
MR-Egger interceptc -0.013 -0.038 0.013 0.33
Inverse-variance weighted Triglycerides 1.01 0.70 1.45 0.94 0.19 46.4
MR-Egger 1.21 0.70 2.09 0.50
Weighted median 1.26 0.77 2.06 0.36
MR-PRESSOb NA NA NA NA
MR-Egger interceptc -0.013 -0.044 0.018 0.39
The best causal estimation highlighted in bold.
CI, confidence interval; HDL, high density lipoprotein; LDL, low density lipoprotein; NA, not applicable; Ph, P-value for heterogeneity.
aOdds ratio per 1 SD increase.
bNo significant outliers.
cRegression coefficient (95% CI).













..disturbs valve function and flow, setting in motion an irreversible
cycle of disturbed flow, abnormal pressure, endothelial damage, and
calcification that eventually leads to severe stenosis requiring valve
replacement.50 Once a certain threshold of valve damage has been
crossed, cholesterol-lowering treatment might not be able to halt
progression of aortic valve disease. As aortic stenosis has a long, silent
clinically asymptomatic phase, it is plausible that treatment initiation





Table 4 Two-sample Mendelian randomization estimations showing the effect of plasma lipids on mitral regurgitation
Methods Exposure Odds ratioa 95% CI P-value Ph Q-statistics
Inverse-variance weighted HDL-cholesterol 0.84 0.70 1.02 0.08 0.0009 100.4
MR-Egger 0.96 0.72 1.29 0.80
Weighted median 0.97 0.76 1.23 0.79
MR-PRESSOb NA NA NA NA
MR-Egger interceptc -0.009 -0.024 0.006 0.25
Inverse-variance weighted LDL-cholesterol 1.10 0.93 1.30 0.23 0.12 68.5
MR-Egger 1.07 0.81 1.40 0.65
Weighted median 1.08 0.85 1.37 0.52
MR-PRESSOb NA NA NA NA
MR-Egger interceptc 0.003 -0.014 0.020 0.73
Inverse-variance weighted Total cholesterol 1.12 0.95 1.32 0.14 0.14 84.7
MR-Egger 1.19 0.88 1.60 0.24
Weighted median 1.08 0.85 1.39 0.50
MR-PRESSOb NA NA NA NA
MR-Egger interceptc -0.004 -0.020 0.012 0.65
Inverse-variance weighted Triglycerides 1.31 1.04 1.65 0.02 0.05 54.0
MR-Egger 1.30 0.92 1.85 0.13
Weighted median 1.29 0.96 1.73 0.09
MR-PRESSOb NA NA NA NA
MR-Egger interceptc 0.000 -0.019 0.020 0.97
The best causal estimation highlighted in bold.
CI, confidence interval; HDL, high density lipoprotein; LDL, low density lipoprotein; NA, not applicable; Ph, P-value for heterogeneity.
aOdds ratio per 1 SD increase.
bNo significant outliers.






































Figure 1 Comparison of the total causal estimations considered heterogeneity and pleiotropic effect between plasma lipids and valvular heart dis-
ease risk using two-sample Mendelian randomization. SD, standard deviation; 1 SD is equal to 0.98 mmol/L for low density lipoprotein-cholesterol,
0.41 mmol/L for high density lipoprotein-cholesterol, 1 mmol/L for triglycerides, and 1.10 mmol/L for total cholesterol.















..process that has been triggered by prolonged exposure to raised lipid
levels. A large randomized prospective, placebo vs. high-dose statin
clinical trial in patients with subclinical aortic sclerosis or mild aortic
stenosis would need to be conducted to test whether statin treat-
ment can slow progression to overt aortic stenosis.
Given the established causal link between elevated LP(a) and aortic
stenosis,31 and evidence showing that statin therapy increases LP(a)
levels,51 it is also plausible that some of the expected beneficial LDL-
lowering effects of statins in previous trials have been counteracted




































Figure 2 Comparison of the direct causal estimations between plasma lipids and valvular heart disease risk using multivariable Mendelian random-
ization. SD, standard deviation; 1 SD is equal to 0.98 mmol/L for low density lipoprotein-cholesterol, 0.41 mmol/L for high density lipoprotein-choles-
terol, 1 mmol/L for triglycerides, and 1.10 mmol/L for total cholesterol. The multivariable Mendelian randomization was adjusted to estimate direct
causal effect of each plasma lipids component, independently of any other plasma lipids variables.
Take home figure Schematic overview of the Mendelian randomization framework and key findings.































































































analysis, we adjusted for genetically determined LP(a) yet the risk es-
timate of LDL-cholesterol on aortic stenosis remained virtually
unchanged.
In our study, the estimates used for outcomes are from valvular
heart disease cases, which were obtained from linked hospital elec-
tronic health records, from which we could not assess disease pro-
gression or severity. Disease outcomes may also be affected by a
degree of misclassification as we relied on using routinely collected
data to identify cases, with no access to echocardiographic data for
direct case ascertainment. However, previous studies that relied on
electronic health records to identify outcomes have shown that the
majority of clinically recorded valve disease codes were based on
echocardiographic assessments, and the recorded cases were typical-
ly in the moderate to severe spectrum of the disease.31,52 In addition,
restricting cases to those with a valve replacement therapy as a proxy
for valve severity yielded similar results. Also, our study assumed that
the genetic variants selected as proxy for lipid levels influenced valvu-
lar heart disease only through the exposure of interest. Although it is
impossible to be certain that the variants used in this study do not
have pleiotropic effects, we did not find any evidence in favour of
strong pleiotropy. Finally, the current study relied on genetic data
conducted in a population mostly of European descent, which, des-
pite the benefit of greater genetic homogeneity, limits the generaliz-
ability of the present findings to other ethnicities. It would be
interesting to study whether the observed associations hold true in
populations with different genetic backgrounds.
In this study, we showed that genetically determined exposure to
raised lipid levels, specifically LDL-cholesterol, total cholesterol, and
triglycerides, significantly increased the risk of aortic stenosis. There
was no evidence that such exposure to raised lipid levels were associ-
ated with aortic regurgitation and mitral regurgitation. After adjust-
ment for other lipid components, the finding further confirmed the
causal association between LDL-cholesterol and risk of aortic sten-
osis. In the absence of high-quality evidence from clinical trials, this
study provides the most compelling evidence that lipids play a role in
the aetiology of aortic stenosis. Considering the substantial ethical
and practical implications of conducting large scale RCTs, particularly
for primary prevention, this study could guide clinical decision-making
regarding lipid-lowering treatment, which may contribute to curb the
global epidemic of aortic valve stenosis.
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